caa a22 4500 445356782 CHVBK 20180317142902.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1007/s10072-011-0798-7 doi (NATIONALLICENCE)springer-10.1007/s10072-011-0798-7 Rechallenge with temozolomide in recurrent glioma [Elektronische Daten] [P. Gaviani, A. Silvani, E. Lamperti, A. Botturi, L. Fariselli, G. Simonetti, D. Ferrari, A. Salmaggi] Despite a confirmed survival benefit associated with adjuvant radio- and chemotherapy, the majority of patients with malignant glioma relapse after initial therapy. Recurrent malignant glioma treatment has not been standardised and usually the response rate to standard chemotherapy protocols for recurrent malignant glioma is less than 30%. The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment. The most widely studied regimens in this setting include (1) 21 of 28-day schedule at a dose of 75-100mg/m2/day; (2) 7 of 14-day schedule at a dose of 150mg/m2/day, also referred to as the ‘‘oneweek on/oneweek off'' schedule; (3) Continuous daily schedule at a dose of 50mg/m2/day. An alternative dosing schedule of TMZ may be a reasonable option in patients having high-grade gliomas with recurrence after standard therapy. Springer-Verlag, 2011 Temozolomide nationallicence Recurrent glioma nationallicence Salvage chemotherapy nationallicence Dose-dense nationallicence Gaviani P. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Silvani A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Lamperti E. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Botturi A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Fariselli L. Department of Neurosurgery, U.O. Radiotherapy Fondazione IRCCS. Istituto Neurologico C. Besta, Milan, Italy aut Simonetti G. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Ferrari D. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Salmaggi A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Neurological Sciences Springer Milan 32(2011-11-01), 247-249 1590-1874 32<247 2011 32 10072 https://doi.org/10.1007/s10072-011-0798-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10072-011-0798-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gaviani P. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Silvani A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Lamperti E. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Botturi A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Fariselli L. Department of Neurosurgery, U.O. Radiotherapy Fondazione IRCCS. Istituto Neurologico C. Besta, Milan, Italy aut NATIONALLICENCE 700 1- Simonetti G. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Ferrari D. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Salmaggi A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 773 0- Neurological Sciences Springer Milan 32(2011-11-01), 247-249 1590-1874 32<247 2011 32 10072 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer